Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)

Antiviral Therapy

Volumn 7, Issue 4, 2002, Pages 293-303

  Gibb, Diana M ^a   Walker, A Sarah ^a   Kaye, Steve ^b   De Rossi, Anita ^c   Ait Khaled, Mounir ^d   Pillay, Deenan ^e   Muñoz Fernandez, Maria Angeles ^f   Loveday, Clive ^b   Compagnucci, Alexandra ^g   Dunn, David T ^a   Babiker, Abdel G ^a  

^a Med Res Cncl Clinical Trials Unit   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d GLAXOSMITHKLINE   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS MUTATION;

EID: 0036972280     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G & Pezzotti P. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Journal of the American Medical Association 2000; 284:190-197.
2. Frederick T, Bertolli J & Mascola L. Trends in the incidence of AIDS-Defining conditions among children infected with HIV: 1992-1997. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 2000. Abstract 690.
3. Lindegren ML & Selik R. Trends in selected causes of death among children (<13 yrs) who died with HIV infection, 1987-1998. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 2001. Abstract 676.
4. Haubrich R & Demeter L. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations Journal of AIDS 2001; 26:S51-S59.
5. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using standardised data analysis plan. Antiviral Therapy 2000; 5:41-48.
6. Hirsch MS, Brun-Vezinet F, D'Aquila R, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel. Journal of the American Medical Association 2000; 283:2417-2426.
7. Wahl LM & Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proceedings of the Royal Society of London B Biological Sciences 2000; 267:835-843.
8. Bean P, Patnaik M, Graziano FM & Aziz DC. Therapeutic drug monitoring of antiretroviral agents. American Clinical Laboratory 2000; 19:20-22.
9. Eshleman SH, Krogstad P, Brooks Jackson J, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S & Palumbo P. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). Journal of Infectious Diseases 2001; 183:1732-1738.
10. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359:733-740.
11. Harrigan RP, Montaner JSG, Wegner SA, Verbiest W, Miller V, Wood R & Larder BA. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-1677.
12. Pillay D, Walker AS, Gibb DM, de Rossi A, Kave S, Ait-Khaled M, Muñoz-Fernandez M, Babiker AG, for the Paediatric European Network for Treatment of AIDS (PENTA). Impact of human immunodeficiency virus type 1 subtypes on virological response and emergence of drug resistance in children in the Paediatric European Network for Treatment of AIDS (PENTA 5) trial. Journal of Infectious Diseases 2002; 186:617-625.
13. Arnemvia T. Regression analysis when the dependent variable is truncated. Normal Econometrica 1973; 41:997-1016.
14. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, Weber JN & McClure MO. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15:1493-1502.
15. Cane PA, de Ritter A, Rice P, Wiselka M, Fox R & Pillay D. Resistance mutations in HIV-1 subtype C protease gene from treated and untreated patients in the UK. Journal of Clinical Microbiology 2001; 39:2652-2654.
16. Pieniazek D, Rayfield M, Hu J, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R & Dondero T. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor naïve individuals worldwide. AIDS 2000; 14:1489-1495.
17. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H for the PENTA (Paediatric European Network for Treatment of AIDS) Steering Committee. Adherence to prescribed antiretroviral therapy in human immunodeficiencv virus infected children in the PENTA 5 Trial. Pediatric Infectious Disease Journal (In Press).
18. De Jose MI, Ramos JT, Alvarez S, Jimenez JL & Muñoz-Fernández MA. Vertical transmission of HIV-1 variants resistant to reverse-transcriptase and protease inhibitors Archives of Internal Medicine 2001; 161:2738-2739.
19. Gallego O, de Mendoza C, Pérez-Elias MJ, Guardiola JM, Pedreira J, Dalmau D, Gonzalez J, Moreno A, Arribas JR, Rubio A, Garcia-Arata I, Leal M, Domingo P & Soriano V. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001; 15:1701-1706.
20. Maguire MF, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R, Kleim JP and the AVANTI Study Group. Absence of zidovudine resistance in antiretroviral-naïve subjects following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14:1195-1201.
21. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F & Brun-Vezinet E Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 2000; 283:205-211.
22. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP & Richman DD. Drug susceptibility in HIV infection after rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000; 283:229-234.
23. Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S, for the CNA3003 International Study Team. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine, zidovudine in HIV-1 infected adults with no prior antiretroviral therapy. Antiviral Therapy 2002; 7:43-51.
24. Larder BA, Kemp SD & Harrigan PR. Potential mecahnism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
25. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10:975-981.
26. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in HIV-1 reverse transcriptase required for resistance to carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41:1094-1098.
27. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M & Purdon S. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind trial. AIDS 2000; 14:781-789.
28. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G & Tisdale M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and after addition of zidovudine and lamivudine. AIDS 2000; 14:163-171.
29. Atkinson B, Isaacson J, Knowles M, Mzabel E & Patick AK. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine. Journal of Infectious Diseases 2000; 182:1109-1118.